EFFECTS OF EMPAGLIFLOZIN ON DIASTOLIC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Abstract
The EMPA-HEART CardioLink-6 trial showed a reduction in left ventricular (LV) mass index by cardiac MRI at 6 months in individuals with type 2 diabetes and stable coronary artery disease treated with empagliflozin 10mg daily vs placebo, in addition to standard of care. A secondary analysis of pre-specified echocardiographic parameters to assess changes in diastolic function was performed to provide further insight into the mechanism of LV...
Paper Details
Title
EFFECTS OF EMPAGLIFLOZIN ON DIASTOLIC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Published Date
Oct 1, 2019
Volume
35
Issue
10
Pages
S79 - S79
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History